The Web Site is currently undergoing a major up-date. Expect the launch soon
This page is being up-dated continuously and will display relevant scientific studies, news and interesting facts related to the clinic and patients
DISCONTINUATION OF INJECTABLE TESTOSTERONE 250mg – STILL AVAILABLE IN THE CLINIC
Since 2012 injectable Testosterone has been off the market in Denmark
Injectable testosterone 250/ml has been off the market in Denmark. As a result of the unstable supply of testosterone 250mg, CCC has an unlimited import license form the Danish Health Authorities of this particular formulation. We will have a continuous supply regardless of the current registration status.
Testosterone 250mg/ml is a valuable drug alternative because of its proven and marked clinical effect that is not matched by the longer acting alternative.
Contact the clinic for more information: +45 3312 2361
CONFERENCE REPORTS – RESEARCH HIGHLIGHTS
14.10.2016. Hormones are “again” safe for women
Recent recommendations from the three largest medical menopause societies all agree on the relative safety of hormone replacement therapy. At consultation thorough details will be discussed with the patient prior to treatment
2011-15. Comforting News for Long-term Treatment of Transgenders
A 2011 study concludes that in female-to-male transgenders use of testosterone in doses used for hypogonadal men seemed safe. The study had a median follow up of 18,5 years and followed 365 FTM transsexuals. (Ref: Asscheman H et al. European Journal of Endocrinology (2011))
In 2015 a large review study again confirms the relative safety of long term treatment of adult transgender individuals. (Ref: Weinand BS et al. J Clin. & Translational Endocrin (2015))
IN THE CLINIC
CCC GEARED TOWARDS INDIVIDUAL TREATMENT.
CCC offers efficient treatment alternatives. As a result of the unstable supply and unreasonable expensive commercial testosterone formulations, CCC offers more convenient and cheaper testosterone treatment to certain categories of patients.
Contact the clinic for more information and consultation: +45 3312 2361